- 1. Surgery, chemotherapy or other anti-cancer therapy within 4 weeks prior to trial entry/randomization into the study. Any other therapy for prostate cancer, other than gonadotropin releasing hormone analogue therapy, such as progesterone, medroxyprogesterone, progestins or 5-alpha reductase inhibitors, must be discontinued at least 2 weeks before the first dose of the study drug.